The following clinical trials related to obesity, diabetes and metabolism are being performed at UTHSC:
| Study | Company | Principal Investigator | Title | Status | Co-ordinator | |
|---|---|---|---|---|---|---|
| DECLARE | Brigham & Women’s Hospital | Dr. Dagogo-Jack | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the effect of Dapagliflozin 10mg Once Daily on the incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes. | Closed | James Ekwensi, M.D. – 448-2676 | |
| Rewind | ICON Clinical Research | Dr. Steinberg | The Effect of Dulaglutide on Major Cardiovasular Events in Patients with Type 2 Diabetes:Researching Cardiovascular Events with a Weekly Incretin in Diabetes | Closed | Amy S. Bell M.S., CCRC – 448-1008 | |
| SUSTAIN | Novo Nordisk | Dr. Gosmanov | A long term, randomized, double-blind, placebo-controlled, multinational, multi-center trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. | Closed | Haiming Du, M.D., PhD – 448-1024 | |
| ELIXA | Sanofi-Aventis | Dr. Gosmanov | A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluateCardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. | Completed | NA | |
| CAROLINA | Boehringer | Dr. Steinberg | A multicenter, international, randomized, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovacular risk. | Closed | Amy S. Bell, M.S., CCRC – 448-1008 | |
| LEADER | Novo Nordisk | Dr. Dagogo-Jack | A Long-term, Multi-center, International, Randomized Double-Blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events | Closed | Amy S. Bell, M.S., CCRC – 448-1008 | |
| BI-1245.29 | Boehringer | Dr. Dagogo-Jack | A randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of empagliflozen (10mg, 25mg) administered orally, once daily over 24 weeks in hypertensive black/African American Patients with type 2 diabetes mellitus. | Open to Recruitment | James Ekwensi, M.D. – 448-2676 | |
| CREDENCE | Janessen -Quintiles | Dr. Steinberg | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canaglifozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Neuropathy. | Open to Recruitment | Amy S. Bell, M.S., CCRC – 448-1008 |